China Resources Sanjiu Medical & Pharmaceutical Future Growth
Future criteria checks 1/6
China Resources Sanjiu Medical & Pharmaceutical is forecast to grow earnings and revenue by 9.8% and 9.3% per annum respectively. EPS is expected to grow by 11% per annum. Return on equity is forecast to be 17.6% in 3 years.
Key information
9.8%
Earnings growth rate
11.0%
EPS growth rate
Pharmaceuticals earnings growth | 17.7% |
Revenue growth rate | 9.3% |
Future return on equity | 17.6% |
Analyst coverage | Good |
Last updated | 28 Aug 2024 |
Recent future growth updates
Analysts Are Updating Their China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE:000999) Estimates After Its Second-Quarter Results
Aug 26China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Apr 23Recent updates
Analysts Are Updating Their China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE:000999) Estimates After Its Second-Quarter Results
Aug 26Does China Resources Sanjiu Medical & Pharmaceutical (SZSE:000999) Have A Healthy Balance Sheet?
Aug 09Investors Aren't Buying China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.'s (SZSE:000999) Earnings
Jul 12China Resources Sanjiu Medical & Pharmaceutical (SZSE:000999) Is Increasing Its Dividend To CN¥1.50
Jun 09China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Apr 23An Intrinsic Calculation For China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE:000999) Suggests It's 50% Undervalued
Apr 16Investors Aren't Buying China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.'s (SZSE:000999) Earnings
Mar 20Do China Resources Sanjiu Medical & Pharmaceutical's (SZSE:000999) Earnings Warrant Your Attention?
Feb 28Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 33,183 | 4,332 | 4,394 | 5,523 | 11 |
12/31/2025 | 30,709 | 3,836 | 3,896 | 4,628 | 13 |
12/31/2024 | 27,614 | 3,428 | 2,599 | 4,903 | 12 |
6/30/2024 | 25,699 | 3,374 | 3,995 | 4,783 | N/A |
3/31/2024 | 25,681 | 3,066 | 3,897 | 4,677 | N/A |
12/31/2023 | 24,739 | 2,853 | 3,335 | 4,192 | N/A |
9/30/2023 | 24,577 | 2,899 | 3,068 | 4,039 | N/A |
6/30/2023 | 22,825 | 2,893 | 1,854 | 2,876 | N/A |
3/31/2023 | 20,182 | 2,759 | 1,856 | 2,858 | N/A |
1/1/2023 | 18,079 | 2,449 | 2,055 | 3,006 | N/A |
9/30/2022 | 16,393 | 2,251 | 1,599 | 2,448 | N/A |
6/30/2022 | 16,081 | 2,112 | 1,919 | 2,734 | N/A |
3/31/2022 | 15,715 | 2,253 | 1,254 | 2,055 | N/A |
1/1/2022 | 15,544 | 2,055 | 1,012 | 1,885 | N/A |
9/30/2021 | 15,586 | 1,773 | 1,299 | 2,133 | N/A |
6/30/2021 | 15,623 | 1,919 | 1,489 | 2,213 | N/A |
3/31/2021 | 14,556 | 1,717 | 1,112 | 1,857 | N/A |
12/31/2020 | 13,637 | 1,597 | 1,602 | 2,224 | N/A |
9/30/2020 | 13,920 | 1,710 | 1,346 | 1,976 | N/A |
6/30/2020 | 13,505 | 1,431 | 1,203 | 1,828 | N/A |
3/31/2020 | 14,473 | 1,455 | 1,741 | 2,263 | N/A |
12/31/2019 | 14,794 | 2,099 | 1,411 | 1,949 | N/A |
9/30/2019 | 14,171 | 2,289 | 1,447 | 1,906 | N/A |
6/30/2019 | 14,122 | 2,328 | 1,517 | 2,012 | N/A |
3/31/2019 | 13,530 | 2,176 | 1,396 | 2,009 | N/A |
12/31/2018 | 13,428 | 1,432 | 1,311 | 1,911 | N/A |
9/30/2018 | 13,080 | 1,455 | 1,358 | 1,943 | N/A |
6/30/2018 | 12,594 | 1,387 | 1,397 | 1,906 | N/A |
3/31/2018 | 12,043 | 1,350 | N/A | 1,697 | N/A |
12/31/2017 | 11,120 | 1,302 | N/A | 1,599 | N/A |
9/30/2017 | 10,301 | 1,288 | N/A | 1,577 | N/A |
6/30/2017 | 9,699 | 1,303 | N/A | 1,459 | N/A |
3/31/2017 | 9,307 | 1,260 | N/A | 1,347 | N/A |
12/31/2016 | 8,982 | 1,198 | N/A | 1,392 | N/A |
9/30/2016 | 8,553 | 1,290 | N/A | 1,335 | N/A |
6/30/2016 | 8,485 | 1,258 | N/A | 1,320 | N/A |
3/31/2016 | 8,149 | 1,223 | N/A | 1,341 | N/A |
12/31/2015 | 7,900 | 1,249 | N/A | 1,260 | N/A |
9/30/2015 | 7,709 | 1,160 | N/A | 1,338 | N/A |
6/30/2015 | 7,475 | 1,107 | N/A | 1,330 | N/A |
3/31/2015 | 7,412 | 1,086 | N/A | 1,213 | N/A |
12/31/2014 | 7,277 | 1,036 | N/A | 1,184 | N/A |
9/30/2014 | 6,770 | 938 | N/A | 1,105 | N/A |
6/30/2014 | 6,959 | 1,064 | N/A | 1,152 | N/A |
3/31/2014 | 7,196 | 1,058 | N/A | 1,177 | N/A |
12/31/2013 | 7,293 | 1,109 | N/A | 1,345 | N/A |
9/30/2013 | 7,630 | 1,150 | N/A | 1,369 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 000999's forecast earnings growth (9.8% per year) is above the savings rate (2.9%).
Earnings vs Market: 000999's earnings (9.8% per year) are forecast to grow slower than the CN market (21.9% per year).
High Growth Earnings: 000999's earnings are forecast to grow, but not significantly.
Revenue vs Market: 000999's revenue (9.3% per year) is forecast to grow slower than the CN market (13.4% per year).
High Growth Revenue: 000999's revenue (9.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 000999's Return on Equity is forecast to be low in 3 years time (17.6%).